Description

1. Product Overview: Olanib is a capsule formulation of Olaparib INN 50 mg, a targeted anticancer agent belonging to the class of PARP inhibitors used in BRCA mutation–associated cancers.

2. Composition: Active Ingredient: Olaparib INN 50 mg | Dosage Form: Capsule

3. Pharmacological Class: PARP (Poly ADP-Ribose Polymerase) Inhibitor

4. Mechanism of Action: Olaparib inhibits PARP enzymes involved in DNA repair. This leads to accumulation of DNA damage in cancer cells, inability to repair, and selective cancer cell death, especially in BRCA-mutated tumors.

5. Indications: Ovarian cancer with BRCA mutation | HER2-negative breast cancer with BRCA mutation | Pancreatic cancer with germline BRCA mutation | Prostate cancer with HRR gene mutations

6. Dosage & Administration: As prescribed by oncologist | Oral use | Swallow whole with water | With or without food

7. Clinical Benefits: Targeted cancer therapy | Delays disease progression | Improves progression-free survival | Oral convenience

8. Contraindications: Hypersensitivity to Olaparib or any component

9. Precautions: Use under oncologist supervision | Monitor blood counts regularly | May cause anemia or fatigue | Avoid use in pregnancy

10. Drug Interactions: CYP3A inhibitors (ketoconazole) | CYP3A inducers (rifampicin, phenytoin)

11. Special Populations: Pregnancy contraindicated | Lactation not recommended | Pediatric safety not established | Dose adjustment in renal/hepatic impairment

12. Adverse Effects: Nausea | Fatigue | Anemia | Decreased appetite

13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children

14. Packaging: Capsule in blister or bottle pack

15. Manufacturer: Everest Pharmaceutical Ltd.